Abstract
Hydroxamic acids are a promising class of chemical compounds with proven antitumor potential, primarily due to their ability to inhibit the activity of histone deacetylase enzymes. The analysis of modern experimental data shows a wide range of biological activities of hydroxamic acids, which make them equally worthy candidates for the fight against neuropathologies. A characteristic feature of hydroxamic acids is their ability to act simultaneously on several promising molecular targets for the correction of both neuropathologies and oncological diseases, thereby exhibiting multifunctionality. This review discusses the effect of hydroxamic acids on key parts of cancer and neurodegenerative disorders' pathogenesis. Pathological changes in the processes associated with oxidative stress, the functioning of mitochondria, and the activity of metal enzymes of the class of histone deacetylases, as the main links in the epigenetic regulation of pathological conditions, are such molecular targets.
Keywords: Hydroxamic acids, cancer, neurodegenerative diseases, oxidative stress, mitochondria, histone deacetylase.
Current Medicinal Chemistry
Title:The Hydroxamic Acids as Potential Anticancer and Neuroprotective Agents
Volume: 28 Issue: 39
Author(s): Margarita E. Neganova, Sergey G. Klochkov, Yulia R. Aleksandrova and Gjumrakch Aliev*
Affiliation:
- Institute of Physiologically Active Compounds of Russian Academy of Sciences, Chernogolovka,Russian Federation
Keywords: Hydroxamic acids, cancer, neurodegenerative diseases, oxidative stress, mitochondria, histone deacetylase.
Abstract: Hydroxamic acids are a promising class of chemical compounds with proven antitumor potential, primarily due to their ability to inhibit the activity of histone deacetylase enzymes. The analysis of modern experimental data shows a wide range of biological activities of hydroxamic acids, which make them equally worthy candidates for the fight against neuropathologies. A characteristic feature of hydroxamic acids is their ability to act simultaneously on several promising molecular targets for the correction of both neuropathologies and oncological diseases, thereby exhibiting multifunctionality. This review discusses the effect of hydroxamic acids on key parts of cancer and neurodegenerative disorders' pathogenesis. Pathological changes in the processes associated with oxidative stress, the functioning of mitochondria, and the activity of metal enzymes of the class of histone deacetylases, as the main links in the epigenetic regulation of pathological conditions, are such molecular targets.
Export Options
About this article
Cite this article as:
Neganova E. Margarita , Klochkov G. Sergey , Aleksandrova R. Yulia and Aliev Gjumrakch*, The Hydroxamic Acids as Potential Anticancer and Neuroprotective Agents, Current Medicinal Chemistry 2021; 28 (39) . https://dx.doi.org/10.2174/0929867328666201218123154
DOI https://dx.doi.org/10.2174/0929867328666201218123154 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Promotion of Apoptosis in Cancer Cells by Selective Purine-Derived Pharmacological CDK Inhibitors: One Outcome, Many Mechanisms
Current Pharmaceutical Design The Genus Glycosmis [Rutaceae]: A Comprehensive Review on its Phytochemical and Pharmacological Perspectives
The Natural Products Journal Kinase Inhibitors Targeting Anti-angiogenesis as Anti-cancer Therapies
Current Angiogenesis (Discontinued) Patent Selections
Recent Patents on Biotechnology CD20-based Immunotherapy of B-cell Derived Hematologic Malignancies
Current Cancer Drug Targets 2-Chloroadenosine and Human Prostate Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Specific Immune Intervention with Monoclonal Antibodies for the Treatment of Multiple Sclerosis
Current Medicinal Chemistry Dendritic Cell Immunotherapy for Melanoma
Reviews on Recent Clinical Trials Mitochondrial Effects of Organoselenium and Organotellurium Compounds
Current Organic Chemistry Anticancer Drugs Discovery and Development from Marine Organisms
Current Topics in Medicinal Chemistry ER Stress and Autophagy
Current Molecular Medicine The ARRONAX Project
Current Radiopharmaceuticals Phosphonic Esters and their Application of Protease Control
Current Pharmaceutical Design Antibody-Drug Conjugate Targets
Current Cancer Drug Targets Safety and Efficacy of Immune Checkpoint Inhibitors in Children and Young Adults with Haematological Malignancies: Review and Future Perspectives
Cardiovascular & Hematological Agents in Medicinal Chemistry Recent Advances in Small Molecule Prodrugs for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Molecular Targeting of Cell Death Signal Transduction Pathways in Cancer
Current Signal Transduction Therapy Thymic Immunosuppressive Pentapeptide (TIPP) Shown Anticancer Activity in Breast Cancer and Chronic Myeloid Leukemia Both <i>In Vitro</i> and <i>In Vivo</i>
Protein & Peptide Letters Utilising Nanotechnology and Nanosystems for Treatment of Rare Diseases
Pharmaceutical Nanotechnology Design and Synthesis of Coumarin Derivatives as Novel PI3K Inhibitors
Anti-Cancer Agents in Medicinal Chemistry